Clinical trial Recruiting at 1 site Phase 2 Interventional

Using Baitouweng Decoction to treat ulcerative colitis

Official title: Formula-to-Syndrome Effect and Pharmacomicrobiomics Mechanism of Colon Delivery of Baitouweng Decoction for Treating Large Intestine Damp-heat Syndrome of Ulcerative Colitis

Run by The Second Hospital of Nanjing Medical University · NCT06421818 · Data updated 2026-11-12

This study is testing if a traditional herbal remedy called Baitouweng Decoction can help people with ulcerative colitis by trying it in different ways, like taking it by mouth or as an enema, to see which method works best.

More Ulcerative Colitis trials

Quick facts

PhasePhase 2
Study typeInterventional
SexAll
Enrollment144 (estimated)
SponsorThe Second Hospital of Nanjing Medical University
Academic / other
Drugs / interventionsradiation
Locations1 site (Nanjing, Jiangsu)
StatusRecruiting
StartedMay 2024
Main results expectedDecember 30, 2026
Study endsDecember 30, 2026
Registry record updatedMay 21, 2024
Trial IDNCT06421818 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients diagnosed with mild to moderate active ulcerative colitis who exhibit symptoms of large intestine damp-heat syndrome.

Probably not a fit

Patients with severe ulcerative colitis or those who do not meet the specific syndrome criteria may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of Baitouweng Decoction in treating large intestine damp-heat syndrome associated with ulcerative colitis. It employs a multi-center randomized controlled design to compare the outcomes of three different administration methods: colon transendoscopic entral tubing (TET), rectal enema, and oral intake. The study will analyze changes in fecal calprotectin levels, disease condition, and safety over a treatment period of 10 days, while also examining the microbiome and metabolomic changes associated with the treatment. A total of 144 subjects will be enrolled and divided into treatment and placebo groups to assess the efficacy and underlying mechanisms of the decoction.

Why it matters

Potential benefit: If successful, this study could provide a new effective treatment option for patients suffering from ulcerative colitis.

How similar studies have gone: While the use of Baitouweng Decoction is traditional, this specific approach using colon TET is novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients diagnosed with ulcerative colitis;
2. The patients are in mild to moderate active stage with Mayo score of 3-8.
3. Patients with damp-heat syndrome of large intestine according to TCM syndrome differentiation: according to the expert consensus on integrated traditional Chinese and Western medicine diagnosis and treatment of UC, the main symptoms are diarrhea, mucopurulent and bloody stool, abdominal pain, and tenesmus. Secondary symptoms: anal burning, body heat is not Yang, dry mouth and bitter mouth, short red urine. Tongue pulse: tongue red fur yellow greasy, pulse slippery number. The determination of the above 8 syndromes can be made if there are 2 main symptoms and 1-2 secondary symptoms. The tongue pulse is for reference only.
4. The patients who can tolerate Baitouweng Decoction;
5. The patients who tolerance to colonoscopy and TET;
6. The patients who know and agree to participate in the clinical trial.

Exclusion Criteria:

1. The patients are complicated with other diseases that may cause diarrhea, such as infectious colitis, radiation enteritis, Crohn's disease, etc.
2. Patients with heart, brain, lung, liver, kidney and other serious diseases;
3. Patients do not cooperate to complete the clinical trial process;
4. Other cases considered unsuitable for inclusion.

Where it's running

  • Department of Microbiota Medicine & Medical Centre for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu, China
    Recruiting

Study contacts

  • Principal investigator: Faming Zhang, PhD — The Second Hospital of Nanjing Medical University
  • Study coordinator: Faming Zhang, PhD
  • Email: fzhang@njmu.edu.cn
  • Phone: 02558509670

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.